Sector intelligence and perspective

Caladrius Biosciences (CLBS) receives FDA’s RMAT designation for CD34+ for treating Refractory Angina

June 19, 2018

CLBS closed down -$0.12 and is up in the pre-market +$1.00 or +25.32% - BUY

Solid Biosciences (SLDB) clinical hold removed on SGT-001 DMD (Duchenne muscular dystrophy) treatment

June 18, 2018

SLDB closed up +$1.81 on Friday and is up +$2.70 or +10.19% in the pre-market   The clinical hold was imposed in March and came after the unexpected hospitalization of a patient in the P1/2 trial, called Ignite DMD.

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.